Alagille Syndrome Market Size Worth USD 601.56 Million in 2030

1
Alagille Syndrome Market Size Worth USD 601.56
Million in 2030
www.emergenresearch.com
Increasing prevalence of Alagille Syndrome is one
of the key factors driving Alagille Syndrome
market revenue growth
2
Our Model
Market Analysis
Financial Analysis
Distribution Channel Analysis
Brand Analysis
Custom Market Intelligence
Competitor Analysis
Product Analysis
Custom Research
www.emergenresearch.com
Demand Analysis
Risk Analysis
3
Business Plan Parameters
End Use Analysis
Demand Availability Analytics
Market Entry Strategy
Restructuring Revival
New Product Strategy
Product Planning / Strategy
SWOT Analysis
Marketing / Distribution Channel Feasibility
www.emergenresearch.com
Customer Identification Survey
Competitive Landscape / MA Feasibility
www.emergenresearch.com
4
Industries We Cater to
www.emergenresearch.com
5
5
Market Summary
The global Alagille Syndrome market size was USD
361.89 Million in 2021 and is expected to
register a revenue CAGR of 5.8 during the
forecast period, according to latest analysis by
Emergen Research. Increasing prevalence of
alagille syndrome, rising number of clinical
studies and trials in the field of alagille
syndrome-based treatments, and introduction of
novel and advanced diagnostic platforms for early
diagnosis are crucial factors driving market
revenue growth. Alagille syndrome is a
genetically inherited condition that is similar
to other forms of liver disease frequently seen
in infants and young children. According to the
National Institute of Diabetes and Digestive and
Kidney Diseases, Alagille Syndrome affects one in
every 30,000 live newborns. Clinically, Alagille
Syndrome shows as a variety of phenotypes, but is
commonly distinguished by five distinct symptoms,
impaired bile flow, congenital heart disease,
bone issues, a thickening of the crease of
eyelid, and particular facial characteristics.
The diagnostics can be supported by genetic
testing. ALGS is a multisystem disorder with a
wide range of clinical variability, from
preclinical symptoms to modestly abnormal liver
enzymes, a heart issue, butterfly vertebrae, and
posterior embryotoxicity. In addition to
supporting biomarker tests and molecular genetic
analysis, clinical diagnosis of Alagille syndrome
requires proof of a lysosomal acid
alpha-glucosidase enzyme deficiency, which can be
confirmed in dried blood spots or liquid blood
samples. Alagille syndrome may be diagnosed by
means of other tests in addition to a liver
biopsy, which include eye exams, spine x-rays to
look for distinctive changes such as butterfly
vertebrae, abdominal ultrasounds of hepatobiliary
tree (including the liver, pancreas, gall
bladder, and spleen) to look for abnormalities or
rule out other conditions, and blood tests to
assess liver function and find fat-soluble
vitamin deficiencies. Personalized molecular
screening and genetic testing of those who are at
risk can result in early diagnosis and treatment
beginning, potentially improving clinical results
of Alagille syndrome patients. .
www.emergenresearch.com
6
Market Summary
Further key findings from the report suggest The
genetic testing segment accounted for a
significant revenue share in 2021. Genetic
testing is a preferred approach for validating
diagnosis of alagille syndrome (ALGS), which is
brought on by genetic changes in the Jagged 1
(JAG1), Notch 2 (NOTCH2), or 20p12 chromosomal
deletion. Nearly 95 of patients with clinical
symptoms and an ALGS-related mutation are found
through accurate genetic testing. This procedure,
carried out by a medical expert in a lab setting,
entails cellular DNA extraction and analysis to
find genetic abnormalities that might be the
disease's etiology. Genetic testing can help to
predict patient outcomes, recurrence risk, and
medical care by identifying gene mutations
related to ALGS. Prenatal genetic testing (DNA
samples taken during pregnancy) or
preimplantation genetic testing (DNA samples
taken from embryos created through in vitro
fertilization) can aid in early detection of ALGS
in fetus if one or both parents have the
condition. These are major factors driving growth
of this segment. The hospitals segment accounted
for a significant revenue share in 2021. Many
hospitals are working on novel and improved ways
to facilitate in the early detection of alagille
syndrome, with the goal of quickly transferring
patients with mild symptoms to expert centers.
Patients would be able to be properly tested and
diagnosed, allowing them to begin treatment as
soon as possible. In addition, hospital doctors
and medical specialists are providing
individualized methods for all forms of alagille
syndrome and additional supportive drugs that
address the condition's symptoms and
problems. The Europe market accounted for a
moderate revenue share in 2021. Experimental
drugs prepared for alagille syndrome have been
gaining an increasing number of approvals in the
recent years.. Request Free Sample Copy_at_
https//www.emergenresearch.com/request-sample/120
9
www.emergenresearch.com
7
Market Summary
Emergen Research has segmented the global
alagille syndrome market based on diagnostic
method, treatment type, treatment centers, and
region Diagnostic Method Outlook (Revenue, USD
Million 2019-2030) Genetic Testing Liver
Biopsy Heart and Blood Vessel Tests X-ray
Imaging Abdominal Ultrasound Kidney Function
Tests Treatment Type Outlook (Revenue, USD
Million 2019-2030) Drug Medications Ileal Bile
Acid Transporter (IBAT) inhibitors Ursodeoxycholic
Acid Cholestyramine Rifampicin Late Stage
Pipeline Drugs Others Read More_at_
https//www.emergenresearch.com/industry-report/al
agille-syndrome-market
8
Parameter Details
Market Size Estimation Period 2020-2028
Base Year Considered 2020
Historical Data 2017-2019
Forecast Period 2021-2027
Quantitative Units Revenue in USD million CAGR from 2020 to 2028
Segments Covered Types, Application, End-Users, Regions more.
Countries Included The U.S., Germany, U.K., Italy, China, India, Japan, Brazil
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Regions Scope North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Customization Scope 10 hours of free customization expert consultation
Pricing and Purchase Options Explore Different Purchase Options Request for Discount to Avail New Year Discount
MARKET SEGMENTATION
www.emergenresearch.com
9
Regional Share Dynamics
www.emergenresearch.com
10
About Us
At Emergen Research, we believe in advancing with
technology. We are a growing market research and
strategy consulting company with an exhaustive
knowledge base of cutting-edge and potentially
market-disrupting technologies that are predicted
to become more prevalent in the coming
decade. Our expertise umbrellas the
technological environment of all major
industries, and our services help you map your
actions to ensure optimal yield. Our analysts
utilize their market proficiency to offer
actionable insights that help our clients
implement profitable strategies and optimize
their return on investment. Our services are
wide-ranging, right from technological
environment analysis to technological profiling
that highlights the existing opportunities in the
market you can capitalize on to stay ahead of
your competitors.
www.emergenresearch.com
11
Lets Talk Contact Information
Reach out to us and our Research Executives will
ensure you get the report that meets all your
requirements and address all your concerns.
14671 110 Avenue, Surrey, British Columbia, V3R2A9
www.emergenresearch.com
www.emergenresearch.com
sales_at_emergenresearch.com
1 [phone]